Agonist activity of antiestrogen-receptor complexes to regulate urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) endogenous gene expression in breast cancer cells

Cancer Letters

Volumn 125, Issue 1-2, 1998, Pages 215-220

  Levenson, Anait S ^a   Svoboda, Kristen M ^a   Kwaan, Hau C ^a   Jordan, V Craig ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Antiestrogens; Estrogen receptor; Plasminogen activator inhibitor type 1; Urokinase plasminogen activator

Indexed keywords

4 HYDROXYTAMOXIFEN; ANTIESTROGEN; ESTRADIOL; ESTROGEN RECEPTOR; FULVESTRANT; PLASMINOGEN ACTIVATOR INHIBITOR 1; RALOXIFENE; UROKINASE;

ARTICLE; BREAST CANCER; CANCER CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; NORTHERN BLOTTING; PRIORITY JOURNAL;

BREAST NEOPLASMS; ESTROGEN ANTAGONISTS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PIPERIDINES; PLASMINOGEN ACTIVATOR INHIBITOR 1; RALOXIFENE; RECEPTORS, ESTROGEN; RNA, MESSENGER; TAMOXIFEN; TUMOR CELLS, CULTURED; URINARY PLASMINOGEN ACTIVATOR;

EID: 0032513083     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(97)00516-8     Document Type: Article

References (14)

1. Berry M., Metzger D., Chambon P. Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J. 9:1990;2811-2818.
2. Katzenellenbogen J.A., O'Malley B.W., Katzenellenbogen B.S. Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. Mol. Endocr. 10:1996;119-131.
3. Rochefort H. Oestrogen- and antioestrogen-regulated genes in human breast cancer. Ciba Found. Symp. 191:1995;254-265.
4. A.S. Levenson, D.A. Tonetti, V.C. Jordan, The oestrogen-like effect of 4-hydroxytamoxifen on induction of transforming growth factor alpha mRNA in MDA-MB-231 breast cancer cells stably expressing the oestrogen receptor, Br. J. Cancer (1998), submitted.
5. Levenson A.S., Catherino W.H., Jordan V.C. Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor. J. Steroid Biochem. Mol. Biol. 60:1997;261-268.
6. A.S. Levenson, H.C. Kwaan, K.M. Svoboda, I.M. Weiss, S. Sakurai, V.C. Jordan, Oestradiol regulation of the components of the plasminogen-plasmin system in MDA-MB-231 human breast cancer cells stably expressing the oestrogen receptor, Br. J. Cancer (1998), submitted.
7. Catherino W.H., Wolf D.M., Jordan V.C. A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analogue. Mol. Endocr. 9:1995;1053-1063.
8. Wakeling A.E. Use of pure antiestrogens to elucidate the mode of action of estrogens. Biochem. Pharmacol. 49:1995;1545-1549.
9. Jordan V.C., Gradishar W.J. Molecular mechanisms and future uses of antiestrogens. Mol. Aspects Med. 18:1997;168-225.
10. Yang N.N., Venugopalan M., Hardikar S., Glasebrook A. Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifene. Science. 273:1996;1222-1225.
11. Webb P., Lopez G.N., Uht R.M., Kushner P.J. Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol. Endocr. 9:1995;443-456.
12. Umayahara Y., Kawamori R., Watada H., Imano E., Iwama N., Morishima T., Yamasaki Y., Kajimoto Y., Kamada T. Estrogen regulation of the insulin-like growth factor I gene transcription involves an AP-1 enhancer. J. Biol. Chem. 269:1994;16433-16442.
13. Philips A., Chalbos D., Rochefort H. Estradiol increases and anti-estrogens antagonize the growth factor-induced activator protein-1 activity in MCF-7 breast cancer cells without affecting c-fos and c-jun synthesis. J. Biol. Chem. 268:1993;14103-14108.
14. Black L.J., Jones C.D., Falcone J.F. Antagonism of estrogen action with a new benzothiophene-derived antiestrogen. Life Sci. 32:1983;1031-1036.